retatrutide clinical trials safety data study sees significant weight loss in obesity drug study Retatrutide FDA Approval Status 2026:

Unlike shorter-acting GLP-1 agonists, semaglutide can be injected at any time of day, with or without food, maintaining therapeutic plasma concentrations throughout the week

Expansile dermal nests with diffuse cytologic atypia, lack of maturation with depth, significant pagetoid spread of intraepidermal melanocytes, effacement of the epidermis, conspicuous mitoses, and asymmetry should all prompt concern for melanoma

The larger the area of elevation, the more this matters, which is why a full body lift (belt lipectomy) carries a different risk profile than a limited abdominoplasty (tummy tuck)

Drug approval announcement, January 2025